Pralsetinib, a highly selective RET tyrosine kinase inhibitor, has demonstrated significant antitumor activity and good tolerability in patients with RET fusion-positive metastatic NSCLC (7), and has been approved for this indication (8). The gene discussed is RET; the disease is non-small cell lung carcinoma.